$Caribou Biosciences (CRBU.US)$ buy and don’t miss the ride ...
$Caribou Biosciences (CRBU.US)$ buy and don’t miss the ride man!
Caribou Biosciences (Nasdaq: CRBU) reported first clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed or refractory multiple myeloma. The 450x10^6 CAR-T cell dose is the recommended dose for expansion (RDE); dose expansion is planned to start by year-end with data expected in 2026. In 12 BCMA-naïve patients at the RDE (median follow-up 8.3 months) the trial showed 92% ORR, 75% ≥CR, and 91% MRD negativity (≤10^-5). Safety was described as manageable but included cytopenias, infections and isolated serious adverse events.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Market Insights
Hot Topics
Trump's 'Taco deal' sparks market rebound : Market rebound sustainable ?
1. If tariffs pause, which sectors benefit first? 2. Trump's "threat-compromise" cycle normalizes—how to hedge across assets?
Moo Options Explorer
Apr 7 17:28
Weekly roundup: Tariff turmoil and recession fears dominate
71893145 : already dropped from close to 8
102116415 OP 71893145 : short sellers tried to bring it down. its a trend now. you can check and i am sure they are slowly buying it up.